Market News AIOpen the app

MLTX stock news · MoonLake Immunotherapeutics

Stories about MoonLake Immunotherapeutics (MLTX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for MLTX

Follow MoonLake Immunotherapeutics (MLTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MLTX
Free on the App Store and Google Play, or on the web.
  1. Nov 4, 2026, 8:55 AM ET · Market

    MoonLake Immunotherapeutics shared its financial results and business updates for the quarter ending September 30, 2026.

    Neutral

    MoonLake announced results for the quarter ended September 30, 2026, but this filing gives no results figures. It does not show a change in the company's outlook.

  2. Sep 30, 2026, 4:23 PM ET · Trial

    MoonLake Immunotherapeutics says it has sent a request to the FDA to approve sonelokimab for a skin condition.

    Good for MLTX

    MoonLake submitted an application seeking FDA approval for sonelokimab, a positive step toward possible sales. The FDA has not yet accepted it for review or approved it.

  3. Aug 10, 2026, 1:30 PM ET · Market

    Late-stage trial reveals encouraging results for MoonLake's psoriatic arthritis treatment.

    Good for MLTX

    MoonLake Immunotherapeutics announced promising results from its Phase 3 trial for sonelokimab, which met all primary and secondary endpoints for treating psoriatic arthritis. Despite a short-term stock decline, the long-term implications of successful trial results could lead to significant market opportunities, especially with plans for further trials and indications.